Sharp, part of UDG Healthcare plc, has announced that Frank Lis has joined as President of Sharp Clinical Services. In this role, Frank will have global responsibility for Sharp Clinical Services, which is the specialist clinical supply chain services business unit of the Sharp Packaging Services division of UDG Healthcare plc.
Working from state-of-the-art facilities across the US and Europe, Sharp provides unique and often complex commercial and clinical supply chain solutions to the pharmaceutical and biotechnology industries. Services provided include analytical testing, formulation development, clinical manufacturing, packaging, logistics and IRT.
Frank has over 20 years’ experience working for contract drug development organisations with responsibilities including operations, quality and business development. He has established and built analytical, formulation development, clinical manufacturing and clinical supply chain organisations as well as developing and executing strategic growth plans that have enabled these organisations to realise double digit revenue and EBITDA growth. Prior to joining Sharp, Frank was Vice President of Innovation and Strategic Accounts at Catalent Pharma Solutions. Previous roles include Vice President and General Manager of Catalent’s clinical supply services business and VP of Sales and Marketing at Cardinal Health PT&S.
Frank commented: ‘I am thrilled to have joined Sharp and the wider UDG Healthcare team as they continue to grow the clinical services business unit in the US and Europe. It is an exciting time to have joined this fantastic leadership team as we continue to partner with our customers to provide them with unique and complex solutions for their drug development and clinical supply chain needs.’
Mike O’Hara, Managing Director of Sharp Packaging Services remarked: ‘I’m delighted that Frank has joined us to lead the Sharp Clinical Services team. Frank’s track record of establishing and running clinical supply organisations as well as executing strategic growth plans to help these organisations realise double digit revenue and EBITDA growth will be a real asset to our organisation in helping us to achieve our own strategic goals.’